10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?

Argenx reported $1.5 billion in global product net sales in its latest quarter, up 60% year over year and 17% quarter over quarter, led by Vyvgart and Vyvgart Hytrulo. The average analyst 12-month price target is about $1,182 versus roughly $919 at the Oct. 2, 2026 market close, implying around 29% upside; 20 of 21 analysts rated the stock a buy. The outlook is supported by potential pipeline growth, but depends on Phase 3 trial results, while China sales fell 62% year over year in Q2 2026.

Analysis

The key market risk is not whether Vyvgart is growing today, but whether that growth can sustain a premium as the franchise expands into additional indications. The near-unanimous bullish rating set creates a high bar: incremental good news may be discounted, while a failed late-stage readout could compress both forward revenue expectations and the multiple. A positive myositis study is encouraging, but it does not establish approval, launch timing, or commercial uptake. Over 1–3 months, watch for enrollment/readout timing and any evidence that quarterly growth is broadening beyond existing indications; over 6–18 months, the value case depends on successful label expansion and execution against FcRn competitors such as UCB and Johnson & Johnson. China weakness is a secondary issue unless it spreads to other markets or signals access/pricing pressure. The contrarian point is that analyst targets are not independent catalysts and may understate downside from correlated trial risk. No valuation inputs or detailed catalyst calendar are provided, so the reported target upside is not a sufficient entry signal.

Key Decisions for Investors

• Do not chase ARGX solely on the consensus target spread. For an existing position, consider keeping exposure but capping event risk with a defined-risk put spread around major Phase 3 readouts; assess option cost and dates before implementation.
• For new risk, wait for the next verified clinical or commercial datapoint rather than treating analyst upgrades as a catalyst. Reassess if sales growth decelerates materially or guidance fails to support continued franchise expansion.
• Monitor trial outcomes in autoimmune myositis, primary ITP, and Sjogren’s, alongside regulatory timing and launch economics. A setback in more than one program would falsify the broad pipeline-expansion thesis and warrant reducing exposure.
• Track whether China weakness remains contained and whether UCB or Johnson & Johnson gain meaningful share in overlapping indications; broader geographic deterioration or competitive displacement would challenge the premium-growth case.